找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Drug Dosing in Obesity; Volume I: Antimicrob Syed Tabish R. Zaidi,Jason A. Roberts Book 2016 Springer International Publishing Switzerland

[復(fù)制鏈接]
樓主: 劉興旺
31#
發(fā)表于 2025-3-26 22:45:54 | 只看該作者
32#
發(fā)表于 2025-3-27 04:17:45 | 只看該作者
Aminoglycoside Dosing in Obesity,ccurate initial dosing regimens can be achieved by using a correction factor for obesity when estimating a volume of distribution (V). While for subsequent doses, therapeutic drug monitoring (TDM) remains an essential tool to guide dosing and to prevent unwanted adverse events such as nephrotoxicity.
33#
發(fā)表于 2025-3-27 07:24:11 | 只看該作者
34#
發(fā)表于 2025-3-27 10:20:30 | 只看該作者
Azole Antifungal Agents, advancements in drug delivery, efficacy, monitoring and side effect profiling. Pharmacokinetic changes and dose guidance for these agents in the obese population will be addressed following a review of the available literature.
35#
發(fā)表于 2025-3-27 17:17:41 | 只看該作者
36#
發(fā)表于 2025-3-27 18:18:55 | 只看該作者
37#
發(fā)表于 2025-3-28 00:26:52 | 只看該作者
Penicillins, sepsis. Clinical efficacy and the prevention of the emergence of resistance are critically dependent upon the correct dosing strategy in order to meet the required time-dependent pharmacodynamic target. Penicillins mainly experience increases in volume of distribution and renal clearance in obese p
38#
發(fā)表于 2025-3-28 02:05:05 | 只看該作者
Cephalosporins,nfections. Compared with other antibiotics such as vancomycin and aminoglycosides, there is a paucity of data on the pharmacokinetics of cephalosporins in obesity and dosing recommendations are scarce. The purpose of this chapter is to review and summarise the published data to assist in developing
39#
發(fā)表于 2025-3-28 06:48:35 | 只看該作者
40#
發(fā)表于 2025-3-28 11:42:06 | 只看該作者
Fluoroquinolones,age form. The pharmacokinetics of this particular class of antibiotics varies significantly among individual agents, thus preventing a uniform approach to dose adjustment. Relatively more data is available for ciprofloxacin and levofloxacin compared to other agents in this class. This chapter outlin
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-31 15:15
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
武城县| 永城市| 民勤县| 迭部县| 堆龙德庆县| 丁青县| 延长县| 积石山| 禹州市| 汉阴县| 榕江县| 万山特区| 弥渡县| 谢通门县| 岑巩县| 彭山县| 迭部县| 潜江市| 阜宁县| 竹山县| 苍南县| 安泽县| 响水县| 奇台县| 汶上县| 阳信县| 沁水县| 武鸣县| 莱阳市| 双江| 湘潭市| 永泰县| 广丰县| 广宗县| 三亚市| 盐城市| 吉安市| 扬中市| 仁怀市| 山西省| 湘阴县|